MEI Pharma, Inc. (MEIP)

MEI Pharma Income Statement

Financials in millions USD. Fiscal year is July - June.

Year	2023	2022	2021	2020	2019
Revenue	48.82	40.7	34.8	27.76	4.92
Revenue Growth (YoY)	19.95%	16.96%	25.36%	464.72%	203.02%
Cost of Revenue	0	0	1.41	2.67	4.26
Gross Profit	48.82	40.7	33.39	25.09	0.65
Selling, General & Admin	33.13	30.54	24.41	16.72	14.6
Research & Development	52.45	85.64	69.4	34.07	32.3
Operating Expenses	85.58	116.18	93.81	50.78	46.9
Operating Income	-36.76	-75.48	-60.42	-25.7	-46.25
Other Expense / Income	-4.93	-21.03	-19.12	21.48	-29.43
Pretax Income	-31.84	-54.45	-41.31	-47.17	-16.82
Income Tax	0	0	0.01	0	0
Net Income	-31.84	-54.45	-41.31	-47.17	-16.82
Shares Outstanding (Basic)	7	6	6	5	4
Shares Outstanding (Diluted)	7	6	6	5	4
Shares Change	6.49%	9.31%	25.69%	25.83%	74.71%
EPS (Basic)	-4.78	-8.75	-7.40	-10.40	-4.80
EPS (Diluted)	-4.78	-9.99	-12.00	-10.40	-15.00
Free Cash Flow	-52.52	-49.23	-32.67	33.36	-29.64
Free Cash Flow Per Share	-7.88	-7.91	-5.81	7.33	-8.33
Gross Margin	100.00%	100.00%	95.95%	90.38%	13.27%
Operating Margin	-75.31%	-185.48%	-173.65%	-92.58%	-940.90%
Profit Margin	-65.22%	-133.80%	-118.73%	-169.96%	-342.20%
Free Cash Flow Margin	-107.59%	-120.95%	-93.90%	120.20%	-603.05%
EBITDA	-30.02	-53.22	-41.02	-47.06	-16.74
EBITDA Margin	-61.50%	-130.77%	-117.89%	-169.56%	-340.55%
Depreciation & Amortization	1.82	1.24	0.29	0.11	0.08
EBIT	-31.84	-54.45	-41.31	-47.17	-16.82
EBIT Margin	-65.22%	-133.80%	-118.71%	-169.95%	-342.18%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).